Ipsen France

Download PDF

Register to download the report. Already a member?

Sign Up


62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Ipsen France


Logo ipsen-01

Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US).

2015 has been Ipsen´s best year since becoming a publicly traded company, marked by their take-off in the US. In 2016 the US will overtake France to become their number one affiliate. Besides an excellent 2015 operating performance, sales grew by more than 10% year-on-year, driven by the successful launch of Somatuline in neuroendocrine tumors in the US and Europe, and the performance of Dysport in aesthetics. Core operating income grew by close to 24%, reflecting continuous transformation and cost monitoring efforts.


Address: 65 Quai Georges Gorse 92100, Boulogne-Billancourt,France

Tel: +33 (0)1 58 33 50 00

Web: http://www.ipsen.com/en/ipsen-worldwide



Find a company:

Jobs from Indeed


Download PDF

First Name:

Last Name: